Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors

Journal of Medicinal Chemistry

Volumn 41, Issue 10, 1998, Pages 1581-1597

  Martin, Stephen F ^a   Dorsey, Gordon O ^a   Gane, Todd ^a   Hillier, Michael C ^a   Kessler, Horst ^b   Baur, Matthias ^b   Mathä, Barbara ^b   Erickson, John W ^c   Bhat, T Nagarajan ^c   Munshi, Sanjeev ^c   Gulnik, Sergei V ^c   Topol, Igor A ^c  

^a The University of Texas at Austin   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPROPANE DERIVATIVE; PROTEINASE INHIBITOR;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEAR OVERHAUSER EFFECT; X RAY CRYSTALLOGRAPHY;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLOPROPANES; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; OLIGOPEPTIDES; PROTEIN STRUCTURE, SECONDARY; SOLUTIONS;

EID: 15144354436     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980033d     Document Type: Article

References (109)

1. 13C]Cyclosporin A Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. Biochemistry 1991, 30, 6574-6583. FK506. Solution and X-ray: (e) Karuso, P.; Kessler, H.; Mierke, D. F. Solution Structure of FK506 from Nuclear Magnetic Resonance and Molecular Dynamics. J. Am. Chem. Soc. 1990, 112, 9434-9436. (f) Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidyl-Prolyl Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757. Complex: (g) van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin Immunosuppressant Complex. Science 1991, 252, 839-842.
2. 13C]Cyclosporin A Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. Biochemistry 1991, 30, 6574-6583. FK506. Solution and X-ray: (e) Karuso, P.; Kessler, H.; Mierke, D. F. Solution Structure of FK506 from Nuclear Magnetic Resonance and Molecular Dynamics. J. Am. Chem. Soc. 1990, 112, 9434-9436. (f) Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidyl-Prolyl Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757. Complex: (g) van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin Immunosuppressant Complex. Science 1991, 252, 839-842.
3. 13C]Cyclosporin A Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. Biochemistry 1991, 30, 6574-6583. FK506. Solution and X-ray: (e) Karuso, P.; Kessler, H.; Mierke, D. F. Solution Structure of FK506 from Nuclear Magnetic Resonance and Molecular Dynamics. J. Am. Chem. Soc. 1990, 112, 9434-9436. (f) Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidyl-Prolyl Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757. Complex: (g) van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin Immunosuppressant Complex. Science 1991, 252, 839-842.
4. 13C]Cyclosporin A Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. Biochemistry 1991, 30, 6574-6583. FK506. Solution and X-ray: (e) Karuso, P.; Kessler, H.; Mierke, D. F. Solution Structure of FK506 from Nuclear Magnetic Resonance and Molecular Dynamics. J. Am. Chem. Soc. 1990, 112, 9434-9436. (f) Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidyl-Prolyl Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757. Complex: (g) van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin Immunosuppressant Complex. Science 1991, 252, 839-842.
5. 13C]Cyclosporin A Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. Biochemistry 1991, 30, 6574-6583. FK506. Solution and X-ray: (e) Karuso, P.; Kessler, H.; Mierke, D. F. Solution Structure of FK506 from Nuclear Magnetic Resonance and Molecular Dynamics. J. Am. Chem. Soc. 1990, 112, 9434-9436. (f) Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidyl-Prolyl Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757. Complex: (g) van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin Immunosuppressant Complex. Science 1991, 252, 839-842.
6. 13C]Cyclosporin A Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. Biochemistry 1991, 30, 6574-6583. FK506. Solution and X-ray: (e) Karuso, P.; Kessler, H.; Mierke, D. F. Solution Structure of FK506 from Nuclear Magnetic Resonance and Molecular Dynamics. J. Am. Chem. Soc. 1990, 112, 9434-9436. (f) Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidyl-Prolyl Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757. Complex: (g) van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin Immunosuppressant Complex. Science 1991, 252, 839-842.
7. 13C]Cyclosporin A Bound to Cyclophilin: Bound Conformation and Portions of Cyclosporin Involved in Binding. Biochemistry 1991, 30, 6574-6583. FK506. Solution and X-ray: (e) Karuso, P.; Kessler, H.; Mierke, D. F. Solution Structure of FK506 from Nuclear Magnetic Resonance and Molecular Dynamics. J. Am. Chem. Soc. 1990, 112, 9434-9436. (f) Siekerka, J. J.; Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H. A Cytosolic Binding Protein for the Immunosuppressant FK506 has Peptidyl-Prolyl Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757. Complex: (g) van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin Immunosuppressant Complex. Science 1991, 252, 839-842.
8. (a) Kessler, H. NMR-spektroskopishe Methoden Zur Konformationanayse von Peptiden. (Conformations and Biological Activity of Cyclic Peptides.) Angew. Chem., Int. Ed. Engl. 1982, 21, 512-523.
9. (b) Hruby, V. J. Conformational Restrictions of Biologically Active Peptides via Amino Acid Side Chain Groups. Life Sci. 1982, 31, 189-199.
10. (c) Toniolo, C. Conformationally Restricted Peptides Through Short-Range Cyclizations. Int. J. Pept. Protein Res. 1990, 35, 287-300.
11. (a) Spatola, A. F. Peptide Backbone Modifications: A Structure-Activity Analysis of Peptides Containing Amide Bond Surrogates. Conformational Constraints, and Related Backbone Replacements. In Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins; Weinstein, B., Ed.; Marcel Dekker, New York, 1983; Vol. 7, pp 267-357.
12. (b) Hruby, B. J.; Al-Obeidi, F.; Kazmierski, W., Emerging Approaches in the Molecular Design of Receptor-Selective Peptide Ligands: Conformational, Topographical and Dynamic Considerations. Biochem. J. 1990, 268, 249-262.
13. (c) Olson, G. L.; Bolin, D. R.; Bonner, M. P.; Bös, M.; Cook, C. M.; Fry, D. C.; Graves, B. J.; Hatada, M.; Hill, D. E.; Kahn, M.; Madison, V. S.; Ruisiecki, V. K.; Sarabu, R.; Sepinwall, J.; Vincent, G. P.; Voss, M. E. Concepts and Progress in the Development of Peptides Mimics. J. Med. Chem. 1993, 36, 3039-3049.
14. (d) Giannis, A.; Kolter, T. Peptidomimetics for Receptor Ligands. Discovery, Development, and Medical Perspectives. Angew. Chem., Int. Ed. Eng. 1993, 32, 1244-1267.
15. (e) Gante, J. Peptidomimetics-Tailored Enzyme Inhibitors. Angew. Chem., Int. Ed. Eng. 1994, 33, 1699-1720.
16. (f) Wiley, R. A.; Rich, D. H. Peptidomimetics Derived from Natural-Products. Med. Res. Rev. 1993, 13, 327-384.
17. (g) Adang, A. E. P.; Hermkens, P. H. H.; Linders, J. T. M.; Ottenheijm, H. C. J.; van Staveren, C. J. Case Histories of Peptidomimetics. Progression from Peptides to Drugs. Recl. Trav. Chim. Pays-Bas 1994, 113, 63-78.
18. (a) Ball, J. B.; Alewood, P. F. Conformational Constraints: Nonpeptide β-Turn Mimics. J. Mol. Recognit. 1990, 3, 55-64.
19. (b) Kahn, M. Peptide Secondary Structure Mimetics: Recent Advances and Future Challenges. SynLett. 1993, 821-826.
20. Mueller, K.; Obrecht, D.; Knierzinger, A.; Stankovic, C.; Spiegler, C.; Bannwarth, W.; Trzeciak, A; Englert, G.; Labhardt, A. M.; Schönholzer, P. Building Blocks for the Induction or Fixation of Peptide Conformations. In Perspectives in Medicinal Chemistry; Testa, B., Fuhrer, W., Kyburz, E., Giger, R., Eds.; VCH: Weinheim, Germany, 1993; pp 513-532.
21. For example, see: (a) Hagihara, M.; Anthony, N. J.; Stout, T. J.; Clardy, J.; Schreiber, S. L. Vinylogous Polypeptides: An Alternative Peptide Backbone. J. Am. Chem. Soc. 1992, 114, 6568-6570. (b) Smith, A. B., III; Keenan, T. P.; Holcomb, R. C.; Sprengeler, P. A.; Guzman, M. C.; Wood, J. L.; Carroll, P. J.; Hirschmann, R. Design, Synthesis, and Crystal Structure of a Pyrrolinone-Based Peptidomimetic Possessing the Conformation of a β-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes, J. Am. Chem. Soc. 1992, 114, 10672-10674. (c) Chen, L.; Trilles, R. V. Asymmetric Synthesis of a Novel Phenylogous Amino Acid Mimicking an Extended Dipeptide. Tetrahedron Lett. 1992, 36, 8715-8718. (d) Boumendjel, A.; Roberts, J. C.; Hu, E.; Pallai, P. V.; Rebek, J., Jr. Design and Asymmetric Synthesis of β-Strand Peptidomimetics. J. Org. Chem. 1996, 61, 4434-4438. (e) Janetka, J. W.; Raman, P.; Satyshur, K.; Flentke, G. R.; Rich, D. H. Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors. J. Am. Chem. Soc. 1997, 119, 441-442.
22. For example, see: (a) Hagihara, M.; Anthony, N. J.; Stout, T. J.; Clardy, J.; Schreiber, S. L. Vinylogous Polypeptides: An Alternative Peptide Backbone. J. Am. Chem. Soc. 1992, 114, 6568-6570. (b) Smith, A. B., III; Keenan, T. P.; Holcomb, R. C.; Sprengeler, P. A.; Guzman, M. C.; Wood, J. L.; Carroll, P. J.; Hirschmann, R. Design, Synthesis, and Crystal Structure of a Pyrrolinone-Based Peptidomimetic Possessing the Conformation of a β-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes, J. Am. Chem. Soc. 1992, 114, 10672-10674. (c) Chen, L.; Trilles, R. V. Asymmetric Synthesis of a Novel Phenylogous Amino Acid Mimicking an Extended Dipeptide. Tetrahedron Lett. 1992, 36, 8715-8718. (d) Boumendjel, A.; Roberts, J. C.; Hu, E.; Pallai, P. V.; Rebek, J., Jr. Design and Asymmetric Synthesis of β-Strand Peptidomimetics. J. Org. Chem. 1996, 61, 4434-4438. (e) Janetka, J. W.; Raman, P.; Satyshur, K.; Flentke, G. R.; Rich, D. H. Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors. J. Am. Chem. Soc. 1997, 119, 441-442.
23. For example, see: (a) Hagihara, M.; Anthony, N. J.; Stout, T. J.; Clardy, J.; Schreiber, S. L. Vinylogous Polypeptides: An Alternative Peptide Backbone. J. Am. Chem. Soc. 1992, 114, 6568-6570. (b) Smith, A. B., III; Keenan, T. P.; Holcomb, R. C.; Sprengeler, P. A.; Guzman, M. C.; Wood, J. L.; Carroll, P. J.; Hirschmann, R. Design, Synthesis, and Crystal Structure of a Pyrrolinone-Based Peptidomimetic Possessing the Conformation of a β-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes, J. Am. Chem. Soc. 1992, 114, 10672-10674. (c) Chen, L.; Trilles, R. V. Asymmetric Synthesis of a Novel Phenylogous Amino Acid Mimicking an Extended Dipeptide. Tetrahedron Lett. 1992, 36, 8715-8718. (d) Boumendjel, A.; Roberts, J. C.; Hu, E.; Pallai, P. V.; Rebek, J., Jr. Design and Asymmetric Synthesis of β-Strand Peptidomimetics. J. Org. Chem. 1996, 61, 4434-4438. (e) Janetka, J. W.; Raman, P.; Satyshur, K.; Flentke, G. R.; Rich, D. H. Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors. J. Am. Chem. Soc. 1997, 119, 441-442.
24. For example, see: (a) Hagihara, M.; Anthony, N. J.; Stout, T. J.; Clardy, J.; Schreiber, S. L. Vinylogous Polypeptides: An Alternative Peptide Backbone. J. Am. Chem. Soc. 1992, 114, 6568-6570. (b) Smith, A. B., III; Keenan, T. P.; Holcomb, R. C.; Sprengeler, P. A.; Guzman, M. C.; Wood, J. L.; Carroll, P. J.; Hirschmann, R. Design, Synthesis, and Crystal Structure of a Pyrrolinone-Based Peptidomimetic Possessing the Conformation of a β-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes, J. Am. Chem. Soc. 1992, 114, 10672-10674. (c) Chen, L.; Trilles, R. V. Asymmetric Synthesis of a Novel Phenylogous Amino Acid Mimicking an Extended Dipeptide. Tetrahedron Lett. 1992, 36, 8715-8718. (d) Boumendjel, A.; Roberts, J. C.; Hu, E.; Pallai, P. V.; Rebek, J., Jr. Design and Asymmetric Synthesis of β-Strand Peptidomimetics. J. Org. Chem. 1996, 61, 4434-4438. (e) Janetka, J. W.; Raman, P.; Satyshur, K.; Flentke, G. R.; Rich, D. H. Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors. J. Am. Chem. Soc. 1997, 119, 441-442.
25. For example, see: (a) Hagihara, M.; Anthony, N. J.; Stout, T. J.; Clardy, J.; Schreiber, S. L. Vinylogous Polypeptides: An Alternative Peptide Backbone. J. Am. Chem. Soc. 1992, 114, 6568-6570. (b) Smith, A. B., III; Keenan, T. P.; Holcomb, R. C.; Sprengeler, P. A.; Guzman, M. C.; Wood, J. L.; Carroll, P. J.; Hirschmann, R. Design, Synthesis, and Crystal Structure of a Pyrrolinone-Based Peptidomimetic Possessing the Conformation of a β-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes, J. Am. Chem. Soc. 1992, 114, 10672-10674. (c) Chen, L.; Trilles, R. V. Asymmetric Synthesis of a Novel Phenylogous Amino Acid Mimicking an Extended Dipeptide. Tetrahedron Lett. 1992, 36, 8715-8718. (d) Boumendjel, A.; Roberts, J. C.; Hu, E.; Pallai, P. V.; Rebek, J., Jr. Design and Asymmetric Synthesis of β-Strand Peptidomimetics. J. Org. Chem. 1996, 61, 4434-4438. (e) Janetka, J. W.; Raman, P.; Satyshur, K.; Flentke, G. R.; Rich, D. H. Novel Cyclic Biphenyl Ether Peptide β-Strand Mimetics and HIV-Protease Inhibitors. J. Am. Chem. Soc. 1997, 119, 441-442.
26. For the fixation of the side chain orientation of Phe see (a) Zechel, C.; Kessler, H.; Geiger, R. Synthesis and Conformational Studies of Enkephalin-like Cyclic Peptides and Depsipeptides. In Peptides, Structure and Function (Proceedings of the 9th American Peptide Symposium); Deber, C. M., Hruby, V. J., Kopple, K. D., Eds.; Pierce Chemical Co.: Rockford, IL, 1985; pp 507-510. (b) Tourwe, D.; Verschueren, K.; Frycia, A.; Davis, P.; Porreca, F.; Hruby, V. J.; Toth, G.; Jaspers, H.; Verheyden, P.; van Binst, G. Conformational Restriction of Tyr and Phe Side Chains in Opioid Peptides: Information About Preferred and Bioactive Side-Chain Topology. Biopolymers 1996, 38, 1-12.
27. For the fixation of the side chain orientation of Phe see (a) Zechel, C.; Kessler, H.; Geiger, R. Synthesis and Conformational Studies of Enkephalin-like Cyclic Peptides and Depsipeptides. In Peptides, Structure and Function (Proceedings of the 9th American Peptide Symposium); Deber, C. M., Hruby, V. J., Kopple, K. D., Eds.; Pierce Chemical Co.: Rockford, IL, 1985; pp 507-510. (b) Tourwe, D.; Verschueren, K.; Frycia, A.; Davis, P.; Porreca, F.; Hruby, V. J.; Toth, G.; Jaspers, H.; Verheyden, P.; van Binst, G. Conformational Restriction of Tyr and Phe Side Chains in Opioid Peptides: Information About Preferred and Bioactive Side-Chain Topology. Biopolymers 1996, 38, 1-12.
28. For reviews, see: (a) Stammer, C. H. Cyclopropane Amino Acids (2,3- and 3,4-Methanoamino Acids). Tetrahedron 1990, 46, 2231-2254. (b) Burgess, K.; Ho, K.-K.; Moye-Sherman, D. Asymmetric Syntheses of 2,3-Methanoamino Acids. SynLett. 1994, 575-583.
29. For reviews, see: (a) Stammer, C. H. Cyclopropane Amino Acids (2,3- and 3,4-Methanoamino Acids). Tetrahedron 1990, 46, 2231-2254. (b) Burgess, K.; Ho, K.-K.; Moye-Sherman, D. Asymmetric Syntheses of 2,3-Methanoamino Acids. SynLett. 1994, 575-583.
30. 1′ Transition State Analogues. Synthesis of 1(R), 3(R) [1(S), 2(S)] 3-[3-Cyclohexyl-2-[(Boc)amino]-1-hydroxypropyl]-2,2-dimethylcyclopropane Carboxylic Acids. Tetrahedron Lett. 1990, 31, 961-964.
31. (a) Chesnut, D. B.; Marsh, R. E. The Crystal Structure of Cyclopropanecarbohydrazide. Acta Crystallogr. 1958, 11, 413-419.
32. (b) Long, R. E.; Maddox, H.; Trueblood, K. N. The Crystal and Molecular Structure of Cyclopropanecarboxamide. Acta Crystallogr. 1969, B25, 2083-2094.
33. (c) Lynch, V. M.; Austin, R. E.; Martin, S. F.; George, T. Determination of the Absolute Configuration of a Novel Dipeptide Isostere. Acta Crystallogr. 1991, C47, 1345-1347.
34. (d) Itai, A; Toriumi, Y.; Saito, S.; Kagechika, H.; Shudo, K. Preference of cis-Amide Structure in N-Acyl-N-methylanilines. J. Am. Chem. Soc. 1992, 114, 10649-100650.
35. (a) Page, M. I.; Jencks, W. P. Entropie Contributions to Rate Accelerations in Enzymatic and Intramolecular Reactions and the Chelate Effect. Proc. Natl. Acad. Sci. U.S.A. 1971, 68, 1678-1683.
36. (b) Jencks, W. P. On the Attribution and Additivity of Binding Energies. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 4046-4050.
37. (c) Searle, M. S.; Williams, D. H. The Cost of Conformational Order: Entropy Changes in Molecular Associations. J. Am. Chem. Soc. 1992, 114, 10690-10697.
38. (d) Gerhard, U.; Searle, M. S.; Williams, D. H. The Free Energy Change of Restricting a Bond Rotation in the Binding of Peptide Analogues to Vancomycin Group Antibiotics. BioMed. Chem. Lett. 1993, 3, 803-808 and references therein.
39. (a) Fersht, A. R., The Hydrogen Bond in Molecular Recognition. Trends Biol. Sci. 1987, 12, 301-304.
40. (b) Searle, M. S.; Williams, D. H.; Gerhard, U. Partitioning of Free Energy Contributions in the Estimation of Binding Constants: Residual Motions and Consequences for Amide-Amide Hydrogen Bond Strengths. J. Am. Chem. Soc. 1992, 114, 10697-10704.
41. (c) Kato, Y.; Conn, M. M.; Rebek, Jr., J. Hydrogen Bonding in Water Using Synthetic Receptors. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1208-1212.
42. (a) Martin, S. F.; Austin, R. E.; Oalmann, C. J.; Baker, W. R.; Condon, S. L.; DeLara, E.; Rosenberg, S. H.; Spina, K. P.; Stein, H. H.; Cohen, J.; Kleinert, H. D. 1,2,3-Trisubstituted Cyclopropanes as Conformationally Restricted Peptide Isosteres: Application to the Design and Synthesis of Novel Renin Inhibitors. J. Med. Chem. 1992, 35, 1710-1721.
43. 3 Amino Acid Replacement. Bioorg. Med. Chem. Lett. 1992, 2, 1405.
44. Martin, S. F.; Oalmann, C. J.; Liras, S. Cyclopropanes as Conformationally Restricted Peptide Isosteres. Design and Synthesis of Novel Collagenase Inhibitors, Tetrahedron 1993, 49, 3521-3532.
45. Bovy, P. R.; Tjoeng, F. S.; Rico, J. G.; Rogers, T. E.; Lindmark, R. J.; Zablocki, J. A.; Garland, R. B.; McMackins, D. E.; Dayringer, H.; Toth, M. V.; Zupec, M. E.; Rao, S.; Panzer-Knodle, S. G.; Nicholson, N. S.; Salyers, A.; Taite, B. B.; Herin, M.; Miyano, M.; Feigen, L. P.; Adams, S. P. Design of Orally, Active, Non-Peptide Fibrinogen Receptor Antagonists. An Evolutionary Process from the RGD Sequence to Novel Anti-Platelet Aggregation Agents. Bioorg. Med. Chem. 1994, 2, 881-895.
46. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701. (d) Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; March, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylheane-3,4-diol. J. Med. Chem. 1993, 36, 320-330. (e) Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomasselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952. (f) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160. (g) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
47. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701. (d) Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; March, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylheane-3,4-diol. J. Med. Chem. 1993, 36, 320-330. (e) Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomasselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952. (f) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160. (g) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
48. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701. (d) Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; March, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylheane-3,4-diol. J. Med. Chem. 1993, 36, 320-330. (e) Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomasselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952. (f) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160. (g) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
49. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701. (d) Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; March, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylheane-3,4-diol. J. Med. Chem. 1993, 36, 320-330. (e) Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomasselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952. (f) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160. (g) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
50. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701. (d) Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; March, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylheane-3,4-diol. J. Med. Chem. 1993, 36, 320-330. (e) Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomasselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952. (f) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160. (g) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
51. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701. (d) Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; March, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylheane-3,4-diol. J. Med. Chem. 1993, 36, 320-330. (e) Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomasselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952. (f) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160. (g) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
52. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701. (d) Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; March, K. C.; Bryant, P.; Sham, H. L.; Green, B. E.; Betebenner, D. A.; Erickson, J.; Norbeck, D. W. Symmetry-Based Inhibitors of HIV Protease. Structure-activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylheane-3,4-diol. J. Med. Chem. 1993, 36, 320-330. (e) Thaisrivongs, S.; Turner, S. R.; Strohbach, J. W.; TenBrink, R. E.; Tarpley, W. G.; McQuade, T. J.; Heinrikson, R. L.; Tomasselli, A. G.; Hui, J. O.; Howe, W. J. Inhibitors of the Protease from Human Immunodeficiency Virus: Synthesis, Enzyme Inhibition, and Antiviral Activity of a Series of Compounds Containing the Dihydroxyethylene Transition-State Isostere. J. Med. Chem. 1993, 36, 941-952. (f) Waller, C. L.; Oprea, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (I) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally-Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160. (g) Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
53. (h) Smith, A. B., III; Hirschmann, R.; Pasternak, A.; Guzman, M. C.; Yokoyama, A.; Sprengeler, P. A.; Darke, P. L.; Emini, E. A.; Schleif, W. A. Pyrrolinone-Based HIV Protease Inhibitors. Design, Synthesis and Antiviral Activity: Evidence for Improved Transport. J. Am. Chem. Soc. 1995, 117, 11113-11123.
54. 2 Symmetry-Based Diol Inhibitors of HIV-1 Protease. J. Am. Chem. Soc. 1994, 116, 847-855. (e) Smith, A. B., III; Hirschmann, R.; Pasternak, A.; Yao, W. Sprengeler, P. A.; Holloway, M. K.; Kuo, L. C.; Chen, Z.; Darke, P. L.; Schleif, W. A. An Orally Bioavailable Pyrrolinone Inhibitor of HIV-1 Protrease: Computational Analysis and X-ray Crystal Structure of the Enzyme Complex. J. Med. Chem. 1997, 40, 2440-2444.
55. 2 Symmetry-Based Diol Inhibitors of HIV-1 Protease. J. Am. Chem. Soc. 1994, 116, 847-855. (e) Smith, A. B., III; Hirschmann, R.; Pasternak, A.; Yao, W. Sprengeler, P. A.; Holloway, M. K.; Kuo, L. C.; Chen, Z.; Darke, P. L.; Schleif, W. A. An Orally Bioavailable Pyrrolinone Inhibitor of HIV-1 Protrease: Computational Analysis and X-ray Crystal Structure of the Enzyme Complex. J. Med. Chem. 1997, 40, 2440-2444.
56. 2 Symmetry-Based Diol Inhibitors of HIV-1 Protease. J. Am. Chem. Soc. 1994, 116, 847-855. (e) Smith, A. B., III; Hirschmann, R.; Pasternak, A.; Yao, W. Sprengeler, P. A.; Holloway, M. K.; Kuo, L. C.; Chen, Z.; Darke, P. L.; Schleif, W. A. An Orally Bioavailable Pyrrolinone Inhibitor of HIV-1 Protrease: Computational Analysis and X-ray Crystal Structure of the Enzyme Complex. J. Med. Chem. 1997, 40, 2440-2444.
57. 2 Symmetry-Based Diol Inhibitors of HIV-1 Protease. J. Am. Chem. Soc. 1994, 116, 847-855. (e) Smith, A. B., III; Hirschmann, R.; Pasternak, A.; Yao, W. Sprengeler, P. A.; Holloway, M. K.; Kuo, L. C.; Chen, Z.; Darke, P. L.; Schleif, W. A. An Orally Bioavailable Pyrrolinone Inhibitor of HIV-1 Protrease: Computational Analysis and X-ray Crystal Structure of the Enzyme Complex. J. Med. Chem. 1997, 40, 2440-2444.
58. 2 Symmetry-Based Diol Inhibitors of HIV-1 Protease. J. Am. Chem. Soc. 1994, 116, 847-855. (e) Smith, A. B., III; Hirschmann, R.; Pasternak, A.; Yao, W. Sprengeler, P. A.; Holloway, M. K.; Kuo, L. C.; Chen, Z.; Darke, P. L.; Schleif, W. A. An Orally Bioavailable Pyrrolinone Inhibitor of HIV-1 Protrease: Computational Analysis and X-ray Crystal Structure of the Enzyme Complex. J. Med. Chem. 1997, 40, 2440-2444.
59. 2-Symmetric Diamino Alcohols and Diols for Use in HIV Protease Inhibitors. J. Org. Chem. 1992, 57, 5692-5700.
60. (a) Doyle, M. P.; Pieters, R. J.; Martin, S. F.; Austin, R. E.; Oalmann, C. J.; Müller, P. High Enantioselectivity in the Intramolecular Cyclopropanation of Allyl Diazoacetates Using a Novel Rhodium(II) Catalyst. J. Am. Chem. Soc. 1991, 113, 1423-1424.
61. (b) Martin, S. F.; Spaller, M. R.; Liras, S.; Hartmann, B. Enantio- and Diastereoselectivity in the Intramolecular Cyclopropanation of Secondary Allylic Diazoacetates. J. Am. Chem. Soc. 1994, 116, 4493-4494.
62. (c) Doyle, M. P.; Austin, R. E.; Bailey, A. S.; Dwyer, M. P.; Dyatkin, A. B.; Kalinin, A. V.; Kwan, M. M. Y.; Liras, S.; Oalmann, C. J.; Pieters, R. J.; Protopopova, M. N.; Raab, C. E.; Roos, G. H. P.; Zhou, Q.-L.; Martin, S. F. Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium (II) Carboxamide Catalysts. J. Am. Chem. Soc. 1995, 117, 5763-5775.
63. Corey, E. J.; Myers, A. G. Efficient Synthesis and Intramolecular Cyclopropanation of Unsaturated Diazoacetic Esters. Tetrahedron Lett. 1984, 23, 3559-3562.
64. (a) Basha, A.; Lipton, M.; Weinreb, S. M. A Mild, General Method for Conversion of Esters to Amides. Tetrahedron Lett. 1977, 4171-4174.
65. (b) Sibi, M. P. Chemistry of AT-Methoxy-TV-Methylamides. Application in Synthesis. A Review. Org. Prep. Proc. Int. 1993, 25, 15-40.
66. This mixture of 18c and 20 could not be readily separated, but the corresponding carboxylic acids could be easily separated by flash chromatography.
67. Schleucher, J.; Quant, J.; Glaser, S. J.; Griesinger, C. A Theorem Relating Cross Relaxation and Hartmann-Hahn Transfer in Multiple-Pulse Sequences. Optimal Suppression of TOCSY Transfer in ROESY. J. Magn. Reson. A 1995, 112, 144-151.
68. Eberstadt, M; Gemmecker, G.; Mierke, D. F.; Kessler, H. Scalar Coupling Constants- Their Analysis and Their Application for the Elucidation of Structures. Angew. Chem., Int. Ed. Engl. 1995, 34, 1671-1695.
69. Kim Y.; Prestegard, J. H. Motional Properties of Acyl Carrier Protein: Effects on NMR Structural Data. Proteins Struct. Fund. Genet. 1990, 8, 377-385.
70. Mierke, D. F.; Kessler, H. Improved Molecular Dynamics Simulations for the Determination of Peptide Structures. Biopolymers 1993, 33, 1003-1017.
71. Mierke, D. F.; Kessler, H. Combined Use of Homo- and Heteronuclear Coupling Constants as Restraints in Molecular Dynamics Simulations. Biopolymers 1992, 32, 1277-1282.
72. 1H NMR. Proteins: Struct. Fund. Genet. 1993, 17, 297-309.
73. Wüthrich, K.; Billeter, M.; Braun, W. Sequential Resonance Assignments in Protein Proton Nuclear Magnetic Resonanace Spectra. Computation of Sterically Allowed Proton-Proton Distances and Statistical Analysis of Proton-Proton Distances in Single-Crystal Protein Conformations. J. Mol. Biol. 1983, 169, 946-961.
74. Kessler, H.; Schmitt, W. in Encyclopedia of Nuclear Magnetic Resonance; Grant, D. M., Harris, R. K., Eds.; John Wiley & Sons: Chichester, England, 1996; Vol. 6, pp 3527-3537.
75. (a) Pachler, K. G. R. Nuclear Magnetic Resonance (NMR) Study of Some α-Amino Acids. I. Coupling Constants in Alkaline and Acid Medium. Spektochim. Acta 1963, 19, 2085-2092.
76. (b) Pachler, K. G. R. Nuclear Magnetic Resonance Study of Some α-Amino Acids. II. Rotational Isomerism. Spektochim. Acta 1964, 20, 581-587.
77. Frisch, M. J.; et al. Gaussian 94 (Revision D.4); Gaussian, Inc.: Pittsburgh, PA, 1995.
78. Becke, A. D. Universality in the Peroxidase-Oxidase Reaction: Period Doublings, Chaos, Period Three, and Unstable Limit Cycles. J. Phys. Chem. 1993, 98, 5648-5642.
79. Lee, C.; Yang, W.; Parr, R. G. Various Functionals for the Kinetic Energy Density of an Atom or Molecule. Phys. Rev. 1988, B37, 785-789.
80. Baldwin, E. T.; Bhat, T. N.; Gulnik, S. V.; Liu, B.; Topol, I. A.; Kiso, Y.; Mimoto, T.; Mitsuya, H.; Erickson, J. W. Structure of HIV-1 Protease with KN-272, a Tight Binding Allophenylnorstatine. Structure 1995, 3, 581-590.
81. Ohno, Y.; Kiso, Y.; Kobayashi, Y. Solution Conformations of KNI272, a Tripeptide HIV Protease Inhibitor Designed on the Basis of Substrate Transition State: Determinated by NMR Spectroscopy and Simulated Annealing Calculations. Bioorg. Med. Chem. 1996, 4, 1565-1572.
82. Preuss, R.; Schmidt, R. R. C-Glucoside Durch Direkte 1-CLithiierung von 2-Phenylsulfmyl Aktiviertem D-Glucal. (C-Glycosides from Direct C(1)-Lithiation of 2-Phenylsulfinyl Activated D-Glucals.) Liebigs Ann. Chem. 1989, 429-434.
83. Tan, B.; Chia, L. H. L.; Huang, H.; Kuok, M.; Tang, S. Rotational Isomerism in 2,3-Dinitro-2,3-dimethylbutane. J. Chem. Soc., Perkin Trans. 1984, 2, 1407-1415.
84. Topol, I. A., unpublished results.
85. (a) de Meijere, A. Bonding Properties of Cyclopropane and Their Chemical Consequences. Angew. Chem., Int. Ed. Eng. 1979, 18, 809-826.
86. (b) Jorgenson, M. J.; Leung, T. Cyclopropyl Conjugation in Olefinic Esters. Conformational Effects on Ultraviolet Absorption. J. Am. Chem. Soc. 1968, 90, 3769-3774.
87. Hoffmann, R. W. Flexible Molecules with Defined Shape-Conformational Design. Angew. Chem., Int. Ed. Engl. 1992, 31, 1124-1134.
88. Bhat, T. N.; Baldwin, E. T.; Liu, B.; Cheng, Y.-S. E.; Erickson, J. W. Crystal-Structure of a Tethered Dimer of HIV-1 Proteinase Complexed with an Inhibitor. Nat. Struct. Biol. 1994, 1, 552-556.
89. Gulnik, S. V.; Suvorov, L. I.; Liu, B.; Anderson, B.; Mitsuya, H., Erickson, J. W. Kinetic Characterization and Cross-Resistance Patterns of HIV-1 Protease Mutants Selected under Drug Pressure. Biochemistry 1995, 34, 9282-9287.
90. Kageyama, S.; Mimoto, T.; Murakawa, Y.; Nomizu, M.; Ford, H., Jr.; Shirasaka, T.; Gulnik, S.; Erickson, J.; Takada, K.; Hayashi, H.; Broder, S.; Kiso, Y.; Mitsuya, H. Invitro Anti-Human-Immunodeficiency-Virus (HIV) Activities of Transition-State HIV Protease Inhibitors Containing Allophenylnorstatine. Antimicrob. Agents Chemother. 1993, 37, 810-817.
91. Kessler, H.; Gehrke, M.; Griesinger, C. Two-Dimensional NMR Spectroscopy: Background and Overview of the Experiments. Angew. Chem., Int. Ed. Engl. 1988, 27, 490-536.
92. Neuhaus, D.; Williamson, M. The Nuclear Overhauser Effect in Structural and Conformational Analysis; VCH: Weinheim, Germany, 1989.
93. Griesinger, C.; Ernst, R. R. Frequency Offset Effects and Their Elimination in NMR Rotating-Frame Cross-Relaxation Spectroscopy. J. Magn. Reson. 1987, 75, 261-271.
94. Otting, G.; Wüthrich, K. Heteronuclear Filters in Two-Dimensional [Proton-Proton ]-NMR Spectroscopy: Combined Use with Isotope Labelling for Studies of Macromolecular Conformation and Intermolecular Interactions. Q. Rev. Biophys. 1990, 23, 39-96.
95. Kim, Y.; Prestegard, J. H. Measurement of Vicinal Couplings from Cross Peaks in COSY Spectra. J. Magn. Reson. 1989, 84, 9-13.
96. Keeler, J.; Neuhaus, D.; Titman J. J. A Convenient Technique for the Measurement and Assignment of Long-Range Carbon-13 Proton Coupling Constants. J. Chem. Phys. 1988, 146, 545-548.
97. (a) Hagler, A. T.; Lifson, S.; Dauber, P. Consistent Force Field Studies on Intramolecular Forces in Hydrogen-Bonded Crystals. 2. A Benchmark for the Objective Comparison of Alternative Force Fields. J. Am. Chem. Soc. 1979, 101, 5122-5130.
98. (b) DISCOVER Version 95.0, Biosym Technologies, 10065 Barnes Canyon Road, San Diego, CA 92121, USA.
99. Jessen, S. M. Structure of Two Cyclopropane Derivatives: cis-and trans-Caronic Acid. Acta Crystallogr., C 1992, 48, 106-116.
100. (a) Cremer, D.; Gauss, J. Theoretical Determination of Molecular Structure and Conformation. 20. Reevaluation of the Strain Energies of Cyclopropane and Cyclobutane-CC and CH Bond Energies, 1,3 Interactions, and σ-Aromticity. J. Am. Chem. Soc. 1986, 108, 7467-7477.
101. (b) Cremer, D.; Gauss, J. Theoretical Determination of Molecular Structure and Conformation. 16. Substituted Cyclopropanes-An Electron Density Model of Substituent-Ring Interactions. J. Am. Chem. Soc. 1985, 107, 3811-3819.
102. (a) Bystrov, V. F. Spin-Spin Coupling and the Conformational States of Peptide Systems. Prog. Nucl. Magn. Reson. Spectrosc. 1976, 10, 41-81.
103. (b) Kessler, H.; Griesinger, C.; Wagner, K. Peptide Conformations. 42. Conformation of Side Chains in Peptides Using Heteronuclear Coupling Constants Obtained by Two-Dimensional NMR Spectroscopy. J. Am. Chem. Soc. 1987, 109, 6927-6933.
104. 15N-Enriched Human Ubiquitin. J. Am. Chem. Soc. 1995, 117, 1810-1813.
105. (d) Wang, A. C.; Bax, A. Determination of the Backbone Dihedral Angles ø in Human Ubiquitin from Reparameterixed Emperical Karplus Equations. J. Am. Chem. Soc. 1996, 118, 2483-2494.
106. Mierke, D. F.; Kessler, H. Molecular Dynamics with Dimethyl Sulfoxide as a Solvent. Conformation of a Cyclic Hexapeptide. J. Am. Chem. Soc. 1991, 113, 9466-9470.
107. Saulitis, J.; Mierke, D. F.; Byk, G.; Gilon, C.; Kessler, H. Conformation of Cyclic Analogues of Substance P: NMR and Molecular Dynamics in Dimethyl Sulfoxide. J. Am. Chem. Soc. 1992, 114, 4818-4827.
108. Lunney, E. A.; Hagen, S. E. Domagala, J. M.; Humblet, C.; Kosinski, J.; Tait, B. D.; Warmus, J. S.; Wilson, M.; Ferguson, D.; Hupe, D.; Tummino, P. J.; Baldwin, E. T.; Bhat, T. N.; Liu, B.; Erickson, J. W. A Novel Nonpeptide HIV-1 Protease Inhibitor: Elucidation of the Binding Mode and Its Application in the Design of Related Analogs. J. Med. Chem. 1994, 37, 2664-2677.
109. Rashin, A. A. Aspects of Protein Energetics and Dynamics. Prog. Biophys. Mol. Biol. 1993, 70, 73-200.